• 1
    Wilson IB & Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995;273: 5965.
  • 2
    Burke L. Development of health-related quality of life and other guidance for labeling and promotion of FDA-regulated medical products. Value Health 2001;4: 511.
  • 3
    Testa MA & Simonson DC. Assessment of quality of life outcomes. New Engl J Med 1996;334: 83540.
  • 4
    Ware JE, Brook RH, Davies AR, et al. Choosing measures of health status for individuals in general population. Am J Public Health 1981;71: 6205.
  • 5
    Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Control Clin Trials1991;12: 142S58S.
  • 6
    Gill TM & Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272: 61926.
  • 7
    Guyatt GH, Veldhuyzen Van Zanten SJO, Feeny DH, et al. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ 1989;140: 14418.
  • 8
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118: 6229.
  • 9
    Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: What are the necessary measurement properties? J Clin Epidemiol 1992;45: 13415.
  • 10
    Williams JI & Naylor CD. Dissent. How should health status measures be assessed? Cautionary notes on procrustean frameworks. J Clin Epidemiol 1992;45: 134751.
  • 11
    Guillemin F, Baombardier C, Beaton D. Cross cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46: 141732.
  • 12
    O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40: 107987.
  • 13
    Zhang J, Quan H, Ng J, et al. Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997;18: 20421.
  • 14
    Hochberg Y & Tamhane AC. Multiple Comparison Procedures. New York: John Wiley and Sons, 1987.
  • 15
    Hsu JC. Multiple Comparisons. Theory and Methods. New York: Chapman & Hall, 1996.
  • 16
    Fairclough DL & Gelber RD. Quality of life: statistical issues and analysis. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). Philadelphia: Lippincott-Raven Publishers, 1996.
  • 17
    Curran D, Fayers PM, Molenberghs G, et al. Analysis of incomplete quality of life data in clinical trials. In: StaquetMJ, HaysRD, FayersPM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press, 1998.
  • 18
    Fairclough DL. Methods of analysis for longitudinal studies of health-related quality of life. In: StaquetMJ, HaysRD, FayerPM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press, 1998.
  • 19
    Leidy NK, Revicki DA, Geneste B. Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion. Value Health 1999;2: 11327.
  • 20
    Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol 1997;50: 86979.
  • 21
    Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47: 817.
  • 22
    Guyatt GH, Kirshner B, Jaeschke R. Response. A methodologic framework for health status measures: Clarity or oversimplification? J Clin Epidemiol 1992;45: 13535.
  • 23
    McHorney CA, Kosinski M, Ware JE Jr. Comparisons of the costs and quality of norms for the SF-36. Med Care 1994;32: 55167.